Table 1.
Qualitative AD study: adult and adolescent demographic and clinical characteristics
| Adults (n = 15) | Adolescents (n = 6) | |
|---|---|---|
| Age (in years) | ||
| Mean (SD) | 30.4 (12.9) | 13.0 (1.0) |
| Min–max (years) | 19–64 | 12–15 |
| Gender, n (%) | ||
| Female | 11 (73%) | 3 (50%) |
| Race, n (%) | ||
| Asian | 8 (53%) | 5 (83%) |
| Black | 0 (0%) | 1 (17%) |
| Native Hawaiian/Pacific Islander | 1 (7%) | 0 (0%) |
| White | 4 (27%) | 0 (0%) |
| Biracial | 1 (7%) | 0 (0%) |
| Missing | 1 (7%) | 0 (0%) |
| Ethnicity, n (%) | ||
| Non-Hispanic/non-Latino | 13 (87%) | 6 (100%) |
| Education level, n (%) | ||
| Elementary/primary school | 0 (0%) | 3 (50%) |
| Some high school | 0 (0%) | 3 (50%) |
| Some college | 5 (33%) | 0 (0%) |
| Associate degree | 1 (7%) | 0 (0%) |
| Bachelor’s degree | 7 (47%) | 0 (0%) |
| Post-graduate | 1 (7%) | 0 (0%) |
| Trade | 1 (7%) | 0 (0%) |
| Time since first symptom, n (%) | ||
| 1–5 years | 4 (27%) | 3 (50%) |
| 6–10 years | 11 (73%) | 3 (50%) |
| Time since diagnosis, n (%) | ||
| Less than 1 year | 1 (7%) | 0 (0%) |
| 1–5 years | 6 (40%) | 3 (50%) |
| 6–10 years | 8 (53%) | 3 (50%) |
| Medications, n (%)a | ||
| Triamcinolone | 3 (20%) | 1 (17%) |
| Hydrocortisone | 2 (13%) | 1 (17%) |
| Tacrolimus | 3 (20%) | 0 (0%) |
| Crisaborole | 4 (27%) | 2 (34%) |
| Halobetasol | 1 (7%) | 0 (0%) |
| Over the counter | 5 (33%) | 2 (34%) |
| None | 2 (13%) | 1 (17%) |
| Overall health, n (%) | ||
| Fair | 3 (20%) | 2 (34%) |
| Good | 4 (27%) | 3 (50%) |
| Very good | 5 (33%) | 1 (17%) |
| Excellent | 2 (13%) | 0 (0%) |
aDoes not sum to 100% as participants could report multiple medications